Compare S & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | S | LNTH |
|---|---|---|
| Founded | 2013 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.9B |
| IPO Year | 2021 | 2014 |
| Metric | S | LNTH |
|---|---|---|
| Price | $14.36 | $81.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 6 |
| Target Price | $19.50 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 7.2M | 673.6K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.41 |
| Revenue | ★ $1,001,278,000.00 | $343,374,000.00 |
| Revenue This Year | $22.84 | N/A |
| Revenue Next Year | $17.32 | $14.04 |
| P/E Ratio | ★ N/A | $24.57 |
| Revenue Growth | ★ 21.89 | 3.62 |
| 52 Week Low | $11.81 | $47.27 |
| 52 Week High | $21.40 | $108.86 |
| Indicator | S | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 58.68 |
| Support Level | $13.41 | $72.35 |
| Resistance Level | $15.28 | $84.77 |
| Average True Range (ATR) | 0.61 | 2.20 |
| MACD | 0.18 | 0.33 |
| Stochastic Oscillator | 79.53 | 71.11 |
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.